Comparative Oncology Laboratory, University of California, Davis, CA 95616, USA.
FEBS Lett. 2012 May 21;586(10):1397-402. doi: 10.1016/j.febslet.2012.03.052. Epub 2012 Apr 3.
The ubiquitin-dependent proteasome system plays a critical role in many cellular processes and pathogenesis of various human diseases, including cancer. Although there are a large number of E3 ubiquitin ligases, the majority are RING-finger type E3s. Pirh2, a target of p53 transcription factor, contains a highly conserved C(3)H(2)C(3) type RING domain. Importantly, Pirh2 was found to regulate a group of key factors dedicated to the DNA damage response, such as p53, p73, PolH, and c-Myc. Interestingly, Pirh2 was upregulated or downregulated in different types of cancers. These suggest that Pirh2 is implicated in either promoting or suppressing tumor progression in a tissue-dependent manner. This review will focus on the major findings in these studies and discuss the potential to explore Pirh2 as a cancer therapeutic target.
泛素依赖的蛋白酶体系统在许多细胞过程和各种人类疾病(包括癌症)的发病机制中起着关键作用。虽然有大量的 E3 泛素连接酶,但大多数是 RING 指型 E3s。Pirh2 是 p53 转录因子的靶标,含有高度保守的 C(3)H(2)C(3)型 RING 结构域。重要的是,发现 Pirh2 调节一组专门用于 DNA 损伤反应的关键因子,如 p53、p73、PolH 和 c-Myc。有趣的是,Pirh2 在不同类型的癌症中上调或下调。这些表明 Pirh2 以组织依赖的方式参与促进或抑制肿瘤进展。这篇综述将重点介绍这些研究中的主要发现,并讨论将 Pirh2 作为癌症治疗靶点的潜力。